Key Points
- CEO Thomas Zindrick sold 12,673 shares on August 21 at an average price of $3.33 for about $42,201 (reducing his stake by 2.28% to 542,940 shares) and also sold 4,509 shares on November 17 at $5.37 for about $24,213.
- Genelux, a clinical-stage biotech with a market cap around $168 million, reported Q3 EPS of -$0.21 (beating estimates of -$0.23) and carries an average analyst rating of "Moderate Buy" with an average target price of $21.00.
Genelux Corporation (NASDAQ:GNLX - Get Free Report) SVP Yong Yu sold 3,219 shares of the firm's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $3.36, for a total value of $10,815.84. Following the sale, the senior vice president directly owned 146,817 shares of the company's stock, valued at approximately $493,305.12. This represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Yong Yu also recently made the following trade(s):
- On Monday, November 17th, Yong Yu sold 973 shares of Genelux stock. The stock was sold at an average price of $5.37, for a total value of $5,225.01.
Genelux Stock Down 2.0%
Shares of NASDAQ GNLX traded down $0.09 during mid-day trading on Friday, hitting $4.31. 17,302 shares of the company traded hands, compared to its average volume of 191,133. Genelux Corporation has a 1 year low of $1.99 and a 1 year high of $8.53. The stock has a market capitalization of $164.00 million, a price-to-earnings ratio of -4.90 and a beta of 0.06. The business has a 50 day moving average of $5.74 and a two-hundred day moving average of $4.17.
Genelux (NASDAQ:GNLX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. As a group, research analysts anticipate that Genelux Corporation will post -0.88 EPS for the current year.
Analyst Upgrades and Downgrades
GNLX has been the topic of a number of recent analyst reports. Weiss Ratings restated a "sell (e+)" rating on shares of Genelux in a report on Wednesday, October 8th. Maxim Group set a $20.00 target price on shares of Genelux in a research note on Tuesday, October 21st. Lake Street Capital started coverage on Genelux in a report on Tuesday, October 21st. They issued a "buy" rating and a $16.00 target price for the company. Finally, Loop Capital set a $16.00 price target on Genelux in a report on Tuesday, October 21st. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Genelux currently has an average rating of "Moderate Buy" and an average target price of $21.00.
View Our Latest Research Report on GNLX
Institutional Investors Weigh In On Genelux
Several institutional investors have recently made changes to their positions in GNLX. Susquehanna International Group LLP raised its position in Genelux by 140.3% during the third quarter. Susquehanna International Group LLP now owns 52,383 shares of the company's stock valued at $220,000 after acquiring an additional 30,583 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in shares of Genelux by 101.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 37,224 shares of the company's stock worth $156,000 after purchasing an additional 18,734 shares during the last quarter. Creative Planning increased its stake in shares of Genelux by 4.7% during the 3rd quarter. Creative Planning now owns 46,108 shares of the company's stock worth $194,000 after purchasing an additional 2,084 shares during the last quarter. Woodward Diversified Capital LLC raised its holdings in shares of Genelux by 3.7% during the 3rd quarter. Woodward Diversified Capital LLC now owns 1,844,099 shares of the company's stock valued at $7,745,000 after purchasing an additional 65,813 shares in the last quarter. Finally, 5T Wealth LLC lifted its stake in shares of Genelux by 33.9% in the 3rd quarter. 5T Wealth LLC now owns 24,101 shares of the company's stock valued at $101,000 after purchasing an additional 6,100 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors and hedge funds.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
